March 17, 2006
For Immediate Release
Applications of Tissue Engineering in Urology Opens Up Possibilities for Significant Improvement in Treatment of Stress Urinary Incontinence and Renal Disease --According to March 2006 MedMarkets from MedMarket Diligence
FOOTHILL RANCH, CA — Stress urinary incontinence (UI) and kidney failure, as candidate applications of tissue engineering, are examined in the March 2006 issue of MedMarkets and a market and technology report from MedMarket Diligence. Stress UI is a major problem for women and for an increasing number of men. Most of the $16 billion spent each year on incontinence is spent on managing the condition with diapers and undergarments, instead of curing the disorder. Currently, there are few pharmacological and nonpharmacological treatments that provide relief. Surgical treatment, through placement of a suburethral pubovaginal sling, is about 80% effective, but is invasive, subject to surgical complications, rejection and infection. Similarly, acute kidney failure, if not diagnosed quickly and treated effectively, can promptly progress to multi-organ failure. In end-stage renal disease (ESRD), the options are limited and suboptimal: kidney transplant, peritoneal dialysis or hemodialysis.
"We see strong potential for tissue engineering to be applied to urology in these cases, as the technologies look quite promising in producing the desired clinical outcomes," says Patrick Driscoll, publisher of MedMarkets. According to Driscoll, the technological hurdles are significant, but as a result of advances in tissue engineering in other clinical applications (integumentary, bone, others), the hurdles are steadily becoming less daunting.
The March 2006 issue of MedMarkets examines the applications, caseload, technologies, products and their status of development at companies in the market for tissue engineering in urology. Key competitors include: Cook Group, Curis, Encelle, InnovaCell Biotechnologie, LifeCell, RenaMed Biologics and TEI Biosciences, among others. Coverage in the March issue is detailed here. See also the MedMarket Diligence report on Tissue Engineering and Cell Therapy
MedMarket Diligence provides tactical decision-making solutions on medical
technology to the medical products and investment industries. The company
MedMarkets newsletter, a monthly analysis of the market implications of new
medical technologies, and dedicated reports on technology markets. For
additional details, contact Patrick Driscoll at
email or call
949-859-3401 or toll-free (in the U.S.). 1-866-820-1357.